Literature DB >> 26998137

Small bowel adenocarcinoma arising in a patient with hereditary hemorrhagic telangiectasia: A case report.

Yuichiro Yoshioka1, Hiroaki Nozawa1, Junichiro Tanaka1, Takeshi Nishikawa1, Toshiaki Tanaka1, Tomomichi Kiyomatsu1, Kazushige Kawai1, Keisuke Hata1, Shinsuke Kazama1, Hironori Yamaguchi1, Soichiro Ishihara1, Eiji Sunami1, Joji Kitayama1, Toshiaki Watanabe1.   

Abstract

Patients with hereditary hemorrhagic telangiectasia (HHT) are reportedly at a lower overall risk of malignancies, and small bowel adenocarcinoma (SBA) arising in a HHT patient is extremely rare. In this study, the case of a 37-year-old female with HHT who developed a poorly differentiated jejunal adenocarcinoma five years after ileocecal resection for multiple colonic adenomas is presented. The patient underwent curative resection of the cancer invading the ileum and the mesentery of the transverse colon, but had to overcome critical complications perioperatively, stemming from HHT-associated peripheral capillary dilatation and arteriovenous malformation, including nosebleeds and possible infusion-induced air embolism through pulmonary shunts. The patient subsequently received adjuvant chemotherapy including capecitabine and oxaliplatin for 6 months, and currently remains alive without any evidence of recurrence 12 months after the second surgery. This patient with SBA was an instructive case demonstrating the necessity of careful attention during major surgery in HHT.

Entities:  

Keywords:  chemotherapy; complications; hereditary hemorrhagic telangiectasia; small bowel adenocarcinoma; surgical management

Year:  2016        PMID: 26998137      PMCID: PMC4774470          DOI: 10.3892/ol.2016.4173

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  19 in total

1.  Case records of the Massachusetts General Hospital. Case 33-2005. A 43-year-old man with lower gastrointestinal bleeding.

Authors:  Joshua Korzenik; Daniel C Chung; Subba Digumarthy; Kamran Badizadegan
Journal:  N Engl J Med       Date:  2005-10-27       Impact factor: 91.245

2.  Adjuvant chemotherapy for small bowel adenocarcinoma after curative surgery.

Authors:  Dong Hoe Koo; Sung-Cheol Yun; Yong Sang Hong; Min-Hee Ryu; Jae-Lyun Lee; Heung-Moon Chang; Yoon-Koo Kang; Song-Cheol Kim; Duck-Jong Han; Young-Joo Lee; Tae Won Kim
Journal:  Oncology       Date:  2011-07-01       Impact factor: 2.935

3.  A case of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease) with multiple polyps arising in the cecum and appendix.

Authors:  M Kaneko; H Nozawa; J Kitayama; E Sunami; M Akahane; N Yamauchi; Y Furukawa; H Nagawa
Journal:  Acta Gastroenterol Belg       Date:  2011-06       Impact factor: 1.316

Review 4.  Hereditary hemorrhagic telangiectasia.

Authors:  A E Guttmacher; D A Marchuk; R I White
Journal:  N Engl J Med       Date:  1995-10-05       Impact factor: 91.245

Review 5.  Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment.

Authors:  Thomas Aparicio; Aziz Zaanan; Magali Svrcek; Pierre Laurent-Puig; Nicolas Carrere; Sylvain Manfredi; Christophe Locher; Pauline Afchain
Journal:  Dig Liver Dis       Date:  2013-06-21       Impact factor: 4.088

6.  Life expectancy in patients with hereditary haemorrhagic telangiectasia.

Authors:  C Sabbà; G Pasculli; P Suppressa; F D'Ovidio; G Mariano Lenato; F Resta; G Assennato; G Guanti
Journal:  QJM       Date:  2006-04-04

7.  Over expression of endoglin in human prostate cancer suppresses cell detachment, migration and invasion.

Authors:  Yuequin Liu; Borko Jovanovic; Michael Pins; Chung Lee; Raymond C Bergan
Journal:  Oncogene       Date:  2002-11-28       Impact factor: 9.867

8.  Endoglin phosphorylation by ALK2 contributes to the regulation of prostate cancer cell migration.

Authors:  Diana Romero; Aleksandra Terzic; Barbara A Conley; Clarissa S Craft; Borko Jovanovic; Raymond C Bergan; Calvin P H Vary
Journal:  Carcinogenesis       Date:  2009-09-07       Impact factor: 4.944

9.  Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater.

Authors:  Michael J Overman; Gauri R Varadhachary; Scott Kopetz; Rosni Adinin; E Lin; Jeffrey S Morris; Cathy Eng; James L Abbruzzese; Robert A Wolff
Journal:  J Clin Oncol       Date:  2009-01-21       Impact factor: 44.544

10.  Executive summary of the 11th HHT international scientific conference.

Authors:  Helen Arthur; Urban Geisthoff; James R Gossage; Christopher C W Hughes; Pascal Lacombe; Mary E Meek; Paul Oh; Beth L Roman; Scott O Trerotola; Sebastiaan Velthuis; Whitney Wooderchak-Donahue
Journal:  Angiogenesis       Date:  2015-10       Impact factor: 9.596

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.